Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 11;18(1):54.
doi: 10.1186/s12957-020-01818-7.

Left colon as a novel high-risk factor for postoperative recurrence of stage II colon cancer

Liming Wang  1 , Yasumitsu Hirano  2 , Toshimasa Ishii  2 , Hiroka Kondo  2 , Kiyoka Hara  2 , Nao Obara  2 , Shigeki Yamaguchi  2
Affiliations

Left colon as a novel high-risk factor for postoperative recurrence of stage II colon cancer

Liming Wang et al. World J Surg Oncol. .

Abstract

Background: It is not clear whether stage II colon and rectal cancer have the same risk factors for recurrence. Thus, the purpose of this study was to identify the risk factors for postoperative recurrence in stage II colorectal cancer.

Patients and methods: We retrospectively analyzed the data of 990 patients who had undergone radical surgery for stage II colorectal cancer. Patients' pathological features and characteristics including age, sex, family history, body mass index, tumor diameter, gross type of tumor, infiltration degree (T3/T4), tumor grade, perineural invasion, vascular invasion, lymphatic invasion, pathologic examination of lymph node number, and preoperative carcinoembryonic assay (CEA) level was compared between patients with and without recurrence. Finally, the prediction of the left and right colons was analyzed.

Results: The mean ages of the colon cancer and rectal cancer patients were 69.5 years and 66.4 years, respectively. In total, 508 (82.1%) and 285 (76.8%) patients were treated laparoscopically for colon cancer and rectal cancer, respectively, with median follow-up periods of 42.2 months and 41.8 months, respectively. Forty-four recurrences occurred in both the colon cancer (7.1%) and rectal cancer (11.9%) groups. The preoperative serum CEA level and T4 infiltration were significantly higher in recurrent colorectal cancer patients. The postoperative recurrence rate of left colon cancer (descending colon, sigmoid colon) was higher than that of right colon cancer (cecum, ascending colon, transverse colon) (OR 2.191, 95% CI 1.091-4.400, P = 0.027). In COX survival factor analysis of colon cancer, the left colon is one of the independent risk factors (risk ratio 5.377, 95% CI 0.216-0.88, P = 0.02). In disease-free survival (DFS), the left colon has a relatively poor prognosis (P = 0.05). However, in the COX analysis and prognosis analysis of OS, no difference was found between the left colon and the right colon.

Conclusion: Preoperative CEA and depth of infiltration (T4) are high-risk factors associated with recurrence and are prognostic factors in stage II colorectal cancer. Left colon is also a risk factor for postoperative recurrence of stage II colon cancer.

Keywords: Carcinoembryonic antigen; Colorectal cancer; Left colon cancer; Stage II.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Survival outcomes for colorectal cancer patients with CEA ≧ 5 vs. CEA < 5
Fig. 2
Fig. 2
Survival outcomes for colorectal cancer patients with T3 vs. T4
Fig. 3
Fig. 3
Disease-free survival for colorectal cancer patients with CEA ≧ 5 vs. CEA < 5
Fig. 4
Fig. 4
Disease-free survival for colorectal cancer patients with T3 vs. T4
Fig 5
Fig 5
Prognosis of left colon cancer vs. right colon cancer
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 68(6):394-424. - PubMed
    1. Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 2012;17(1):1–29. doi: 10.1007/s10147-011-0315-2. - DOI - PubMed
    1. Akiyoshi T, Kobunai T, Watanabe T. Recent approaches to identifying biomarkers for high-risk stage II colon cancer. Surg Today. 2012;42(11):1037–1045. doi: 10.1007/s00595-012-0324-4. - DOI - PubMed
    1. Meyers BM, Cosby R, Quereshy F, Jonker D. Adjuvant systemic chemotherapy for stages II and III colon cancer after complete resection: a clinical practice guideline. Current oncology. 2016;23(6):418–424. doi: 10.3747/co.23.3330. - DOI - PMC - PubMed
    1. Benson AB, 3rd, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408–3419. doi: 10.1200/JCO.2004.05.063. - DOI - PubMed

Substances

LinkOut - more resources